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Abstract
Background: Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to
investigate the relationship between these metabolic toxicities and mTORi efficacy.
Methods: From 2007 to 2011, metabolic toxicities were retrospectively collected in patients treated with an mTORi
(everolimus, temsirolimus) for a metastatic renal cell carcinoma (mRCC) in a single institution. Patients were eligible if
they have received an mTORi for at least 28 days. Changes in the following parameters were analyzed: lymphocytes,
serum creatinine, glycemia, serum phosphate, liver transaminases, cholesterol, and triglycerides. The efficacy was
assessed by progression-free survival (PFS) and tumor response.
Results: Data were collected from seventy-five patients (everolimus = 44 patients; temsirolimus = 31 patients). Six patients
exhibited a partial response, 42 a stable disease and 15 had a progressive disease (12 missing). After a median follow-up
of 12.8 months, the median PFS was 6.7 months (95% confidence interval: 4.0-9.1 months). Patients with CB had a
statistically more severe absolute increase of glycemia and absolute decrease in phosphatemia (p = 0.002 and p = 0.02
respectively). The Progression Free Survival was significantly higher with the onset rate of hypophosphatemia (p = 0.03)
and hyperglycemia (p = 0.001) and lower with the onset rate of lymphopenia (p = 0.004).
Conclusions: Hyperglycemia, hypophosphatemia and lymphopenia, were significantly associated with tumor response
and/or PFS. Those events, as well as their onset rate, should be prospectively monitored as predictors of response to
mTORi.
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Background
Angiogenesis plays an important role in the invasion
and dissemination of renal cell carcinoma (RCC), and
dysregulation of genes encoding for the vascular endo-
thelial growth factor (VEGF) and its receptors (VEGF-R)
is the mainstay of this process [1]. Molecules targeting
VEGF and VEGF-R have been developed. Tyrosine
kinase inhibitors (TKI) (sunitinib, sorafenib, axitinib,
cabozantinib) and monoclonal antibodies (bevacizumab)
are routinely used as first- or second-line therapy [2–6].
The mammalian target of rapamycin (mTOR) pathway
is downstream of the phosphoinositide 3-kinase and
AKT pathway. Increased levels of phospho-AKT have
been observed in RCC [7]. Therefore, the inhibition of
the mTOR pathway can potentially inhibit the tumor
progression. In phase III controlled trials, temsirolimus
and everolimus have shown antitumoral efficacy in pa-
tients with mRCC. Temsirolimus was compared in
first-line treatment with interferon-α, showing a statisti-
cally significant benefit in favor of temsirolimus for
progression-free survival (PFS) and overall survival (OS)
[8]. In a phase III trial against placebo (RECORD-1),
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everolimus was evaluated in patients with progressive
disease after TKI failure resulting in a clear benefit in
PFS, but not in OS [9]. Those results led to an approved
use of temsirolimus and everolimus in mRCC. All of
these targeted therapies are responsible for toxicities.
Some of them are common for all of antiangiogenic
therapy such as fatigue, anorexia, diarrhea and anemia
whereas other adverse events are class or agent specific
[3–9]. With mTORi, the most frequent clinical adverse
events reported in phase III trials were skin rash, nausea,
mucositis, and diarrhea [8, 9]. A class-specific pulmonary
toxicity is observed in 35% of patients receiving an
mTORi, going from cough to irreversible interstitial pneu-
monitis [10]. The most common metabolic toxicities were
anemia, hypercholesterolemia, hypertriglyceridemia, in-
crease in serum creatinine, and lymphopenia [8, 9].
A relationship between toxicities of antiangiogenics
and their efficacy has been extensively studied. For in-
stance, hypertension and hypothyroidism have been
shown to be associated with a better disease outcome in
patients receiving sunitinib or bevacizumab [11–17]. As
regards mTORi, a relationship has been found between
the occurrence of pneumonitis and a better clinical out-
come for both everolimus and temsirolimus [18].
Some clinical toxicities have been shown to be corre-
lated with efficacy of antiangiogenics and mTORi. For
mTORi, some of these toxicities were directly related to
the inhibition of the mTOR pathways, both in normal
and tumoral tissue. Therefore, it has been proposed to
investigate toxicity as a surrogate marker for mTORi
efficacy [19]. The purpose of the present study was to
evaluate retrospectively the relationship between meta-
bolic toxicities and mTORi efficacy in mRCC patients.
Methods
Patient population
A retrospective study was conducted in single French
institution (Hôpital européen Georges Pompidou, Paris,
France) involving mRCC patients, treated with everoli-
mus or temsirolimus from March 2007 to December
2011. All the treated patients, who met the following
inclusion criteria, were included in the study: mRCC of
any histological subtype; treatment with an mTORi for
at least 28 days; ECOG performance status (PS) 0–2;
grade 0–2 for neutrophils, hemoglobin, platelets, trans-
aminases, and bilirubin; and creatinine clearance >
50 ml/mn. Patients receiving a concurrent antitumoral
agent were not eligible.
Treatment
Temsirolimus and everolimus were administered on a
routine practice according to registered regimens. Intra-
venous temsirolimus was administered at a dose of
25 mg/m2 once a week. Everolimus was administered
orally at a starting dose of 10 mg per day. The duration
of a cycle was 28 days.
According to French guidelines, the occurrence of a
grade 4 toxicity led to a definitive interruption of
mTORi. In case of grade-3 toxicity, the treatment was
discontinued until recovery to grade 1, and then a re-
duced dose administration was permitted. In case of
grade-2 toxicity, the treatment was discontinued until
recovery to grade 1, and then resumed at a similar dose
administration. In case of grade-1 toxicity, the dose was
unchanged.
Safety assessment
Selected biological parameters (white blood cells, serum
creatinine, glycemia, phosphatemia, liver transaminases,
cholesterol, and triglycerides) were assessed every 4 weeks.
Their baseline value was determined within 7 days before
starting the mTOR inhibitor. The most severe toxicity for
each selected biological parameter was reported according
to the Common Toxicity Criteria for Adverse Events
(CTC-AE, version 3.0). The highest absolute change from
baseline (i.e. difference between baseline value and the
worst reported value) was calculated.
Efficacy assessment
The efficacy assessment was performed according to
routine practice every twelve weeks upon Computed
Tomography scan or any appropriated imaging method
(Magnetic Resonance Imaging, bone scan). The tumoral
response was measured using radiological response
based on the RECIST 1.1 criteria. The clinical benefit
(CB) was defined as the addition of radiological partial
response and/or stable disease. The PFS was defined as
the time from mTOR initiation to disease progression or
last assessment, and OS was defined as the time from
treatment start to death or last follow-up.
Statistical analysis
The primary endpoint was the relation between highest
CTC-grade toxicity and tumor response upon RECIST
1.1 criteria. The secondary endpoints were the relation
between: time to highest CTC-grade toxicity and tumor
response upon RECIST 1.1 criteria; highest absolute
change of biological parameters from baseline and
tumor response upon RECIST 1.1 criteria; highest abso-
lute change of biological parameters from baseline and
PFS; and time to highest CTC-grade toxicity and PFS.
The relation between qualitative variables was evalu-
ated using the chi-square test. The relation between
qualitative and quantitative variables was evaluated using
the Student’s t-test. Survival data were computed ac-
cording to the Kaplan-Meier method, categorical data
were compared using the log-rank test, and continuous
data comparisons were performed using the Cox model.
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The hazard ratios (HR) were calculated with 95% confi-
dence interval (95% CI). The relations were considered
as statistically significant for a p-value < 0.05.
Results
Patient and treatment characteristics
Data were collected from seventy-five patients. The main
characteristics of patients at baseline are summarized in
Table 1. The metastatic disease was synchronous of RCC
diagnosis in 18 patients, whereas metachronous metasta-
ses were observed in 41 patients with a median time to
metastases of 23 months. The median number of tumor
sites was 1 (range: 1–4).
Forty-four patients (59%) received everolimus for a
median duration of 221 days (range: 40 to 838 days), and
31 patients (41%) received temsirolimus for a median
duration of 104 days (range: 32 to 504 days). Everolimus
was administered as first-line treatment (RECORD-3
study) in 2 patients (4%), as second-line (RECORD-1) in
9 patients (20%), and as third-line or more in 33 patients
(66%). Temsirolimus was administered as first-line treat-
ment in 6 patients (19%), as second-line in 11 patients
(35%), and as third-line or more in 14 patients (46%).
Metabolic toxicities
The most frequent all-grade toxicities were lymphopenia,
increase in serum creatinine, hypertriglyceridemia, hyper-
cholesterolemia, and hyperglycemia (Table 2). The most
frequent grade 3–4 toxicities were lymphopenia and
hyperglycemia. Overall, everolimus exhibited a higher rate
of toxicity than temsirolimus.
The median time to the highest grade metabolic toxic-
ities ranged between 28 days and 90 days, i.e. between
the first and the third cycle (Table 2). The earlier toxic-
ities were an increase in liver transaminases and hyper-
cholesterolemia, and the later toxicity was the increase
in serum creatinine.
Efficacy
Twelve patients were not assessable for response be-
cause of an early discontinuation related to toxicity.
Sixty-three patients were assessable with partial response
in 6 patients (9.5%), stable disease in 42 patients (66.7%),
and progressive disease in 15 patients (23.8%) (missing
data: 12 patients).
After a median follow-up of 12.! months, the median
PFS was 6.7 months (median PFS for Clear Cell Carcin-
oma was 4.8 months, and median PFS for non Clear Cell
Carcinoma was 10.2 months (NS)). Fifty-five of 75 pa-
tients (73.3%) died of disease, and the median OS was
14 months (median OS for Clear Cell Carcinoma was
14.6 months, and median OS for non Clear Cell Carcin-
oma was 18 months (NS)).
Relation between metabolic toxicities and clinical efficacy
Tumor response and grade of toxicity
A significant relation was found between CB, and all-
grade increase in serum creatinine and liver transami-
nases. An increase in serum creatinine was found in 92%
of patients with CB vs. 46% of those with Progressive
Disease (PD) (p = 0.01); an increase in ASAT was found
in 94% of patients with CB vs. 66% of those with PD
(p = 0.04); and an increase in ALAT was found in 100%
of patients with CB vs. 66% of those with PD (p = 0.01).
For all other biological parameters, the relation was
not significant.






Median (range) 55 (36–85)
Smokers (current or past), n (%) 36 (48)
Histology, n (%)
Clear cell carcinoma 56 (74.7)
Papillary cell carcinoma 8 (10.7)
Mixt cell carcinoma 6 (8)
Sarcomatoid cell carcinoma 3 (4)
Bellini carcinoma 1 (1.3)
Chromophobic cell carcinoma 1 (1.3)
Nephrectomy, n (%) 70 (93.3)






Primary metastases, n (%) 18 (31)
Missing 17
Bone metastases, n (%) 20 (55.6)
Missing 39
Time to metastases, months




≥ 1 51 (68)
Post mTORi anti-cancer treatment 30 (46)
Missing 33
ECOG-PS Eastern Cooperative Oncology Group performance status
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Tumor response and highest change in biological
parameters as continuous variables
Glycemia increased in CB patients and decreased in PD
patients (+61% vs. - 5%; p = 0.002). Hypophosphatemia
was most severe in CB patients compared to PD patients
(− 26% vs. - 9%; p = 0.02). Increase in liver transaminases
was larger in CB patients than in PD patients (ASAT:
+126% vs. +8%, p = 0.004; ALAT: +229% vs. +4%, p =
0.003). For all other biological parameters, the relation
was not significant.
Tumor response and time to highest grade of toxicity
Median time to grade ≥ 2 lymphopenia was shorter in
PD patients than in CB patients (84 days vs. median not
reached; p = 0.01). Median time to grade ≥ 2 hypergly-
cemia was longer in PD patients than in CB patients
(112 vs. 56 days; p = 0.03). No significant differences
were observed in grade-1 toxicities and for the other
parameters.
Table 3 summarized relationship between tumor re-
sponse and toxicity.
Tumor response and time to toxicity
In PD patients compared with CB patients, lymphopenia
occurred significantly faster (− 1%/day versus. - 0.6%/
day; p = 0.03). For all other biological parameters, the
relation was not significant.
PFS and grade of toxicity
There was no significant difference in PFS between
grades of toxicity for all biological parameters.
PFS and highest change in percent of biological parameters
Longer PFS was correlated with an absolute one-percent
increase in glycemia (p = 0.001) and ASAT (p = 0.04)
(HR: 0.96 [95% CI: 0.93-0.98]; HR: 0.98 [95% CI: 0.96-
0.99] respectively) and an absolute one-percent decrease
in phosphatemia (p = 0.03) (HR: 1.04 [95% CI: 1.003-
1.09]). Shorter PFS was correlated with an absolute one-
percent decrease in lymphocytes (p = 0.004) (HR: 1.01
[95% CI: 1.005-1.02]).
For all other biological parameters, the correlation was
not significant.
Table 2 Metabolic toxicities





All grade n (%) Grade 3/4 n (%) All grade n (%) Grade 3/4 n (%) Median (range) Median (range)
Lymphopenia 13 (42) 4 (13) 25 (57) 9 (20) 56 (28; 644) −31 (−79; 168)
Increase in serum creatinine 14 (45) - 27 (61) - 90 (28; 420) 9.5 (−32; 78)
Hyperglycemia 9 (29) 2 (6) 24 (54) 6 (14) 56 (28; 756) 18 (−44; 346)
Hypophosphatemia 2 (6) 1 (3) 11 (25) 3 (7) 56 (28; 168) −22 (−55; 16)
Increase in ASAT 4 (13) - 14 (32) 1 (2) 28 (14-; 280) 47 (−75; 552)
Increase in ALAT 2 (6) - 14 (32) 2 (4) 28 (28; 308) 75 (−68; 1883)
Hypercholesterolemia 13 (42) - 31 (70) 3(7) 28 (28; 392) 32 (−51; 125)
Hypertriglyceridemia 14 (45) - 31 (70) - 56 (14; 224) 85 (−58; 375)
ASAT aspartate aminotransferase, ALAT alanine aminotransferase
Table 3 Relation between tumor response and metabolic toxicities
CTC Grade of Toxicities Highest change in
biological parameters
Median time to CTC Grade
≥ 2 toxicities
CB (%) / PD (%) (p) CB (%) / PD (%) (p) CB (days) / PD (days)
Lymphopenia NA / 84 (0.01)
Increase in serum creatinine 92 / 46 (0.01) +61 / -5 (0.002)
Hyperglycemia 56/112 (0.03)
Hypophosphatemia −26 / -9 (0.02)
Increase in ASAT 94 / 66 (0.04) +126 / +8 (0.004)
Increase in ALAT 100 / 66 (0.01) +229 / +4 (0.003)
Hypercholesterolemia
Hypertriglyceridemia
CB Clinical Benefit, PD Progressive Disease, NA not attained
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Discussion
To our knowledge, this is the first study analyzing retro-
spectively the relationship between metabolic toxicities
and mTORi efficacy in patients with mRCC. Our find-
ings showed that a CB was more frequent when liver
transaminases and serum creatinine increased, and when
absolute changes in glycemia, phosphatemia, and liver
transaminases were higher. A short time to the highest
lymphopenia grade and a long time to the highest hyper-
glycemia grade were correlated with a progressive dis-
ease. The onset rate of lymphopenia was faster in
progressive patients compared with those having a CB.
A longer PFS was associated with an absolute one-
percent increase in glycemia and ASAT and an absolute
one-percent decrease in phosphatemia, whereas an abso-
lute one-percent decrease in lymphocytes was associated
with a shorter PFS. Efficacy of mTORi in this series was
better than expected maybe because of young age and
good performance status (ECOG-PS) of patients.
As regards hypophosphatemia and increase in liver
transaminases, the incidence rates of grade 3–4 toxicities
reported in pivotal phase III trials were 4% and < 1%,
respectively, which were close from our findings [8, 9].
In contrast, there were some discrepancies between our
results and those published in the literature. The rates of
grade 3–4 hyperglycemia and lymphopenia were higher
in our everolimus subgroup than those described in the
literature (13% vs. 4%; 20% vs. 3%, respectively) [9]
whereas the rates of grade 3–4 hyperglycemia were
lower in the temsirolimus subgroup than those reported
in the literature (6% vs. 11%) [8]. These discrepancies
may be due on the one hand to the small sample size,
and on the other hand to a high proportion of patients
(64%) who were treated in third-line or more.
Correlations between efficacy and toxicity were
highlighted in our study by using two approaches: the
classical CTC-AE developed by the National Cancer
Institute, and the assessment of time to highest grade of
toxicity and changes in the absolute rates, correlated
with RECIST tumor response (RECIST 1.1 criteria) and
PFS. The classical CTC-AE scale presents several limita-
tions as, for instance, the assessment is clinician-based
and the reporting is potentially incomplete [20]. Al-
though our findings are of interest, one should keep in
mind several limitations of the study. It was a retrospect-
ive study and, even if the data were prospectively re-
corded, there were several missing data. No correction
for multiple testing has been made and relation with a p
value close to 5% should be taken cautiously. Twelve
patients withdrew treatment because of toxicity before
efficacy assessment: this could be responsible for modifi-
cation of estimation of relationship between efficacy and
toxicity. Furthermore, the lack of significant relationship
can be due to the small sample size (n = 75). Moreover,
we included patients with 6 various RCC histological
subtypes, knowing that these tumors have unequal sensi-
tivity to mTORi inducing a bias in the efficacy assess-
ment. Finally, patients received either everolimus or
temsirolimus. If both drugs have close toxicities, their
frequencies are not similar. This discrepancy could in-
duce a bias in the estimate of toxicity rate. A final poten-
tial bias in this estimate was the line of therapy: some
patients received mTORi as first line (n = 8), whereas
others received mTORi in the salvage setting (n = 67).
The most common toxicities of routinely used antian-
giogenics (sunitinib, sorafenib) are hypertension, fatigue,
hand-foot syndrome, hypothyroidism, increased lipase,
and lymphopenia [21]. Everolimus and temsirolimus
present with a different toxicity profile, leading especially
to frequent metabolic disorders such as hyperglycemia,
hyperlipidemia, and hypophosphatemia [22]. Our choice
was to not analyze the correlations between clinical
toxicities and efficacy of mTORi, such as pneumonitis,
because its incidence was low (around 14%) in previ-
ously published data for everolimus in the RECORD-1
trial [9]. Thereby, the monitoring of metabolic toxicities
seemed more relevant, because of their frequency and
more reproducible assessment methods.
In a series where patients with mRCC were treated with
temsirolimus or interferon, treatment benefit of temsiroli-
mus over interferon was associated with increase in serum
cholesterol [23]. We did not find this relationship in our
population. Several metabolic toxicities can predict effi-
cacy of targeted therapies and should be explored, such as
proteinuria for VEGF pathways inhibitors, hyperglycemia
or hyperlipidemia for mTORi [24]. We hypothesized that
metabolic toxicity could be related to the efficacy because
the occurrence of toxicity can reflect a higher drug expos-
ure. An interindividual pharmacokinetic variability has
been described in patients receiving everolimus in case of
hepatic impairment [25]. It has been also shown that the
Japanese patients presented a modified pharmacokinetics
of temsirolimus, allowing a maximum tolerated dose of
15 mg/m2 once a week instead of 25 mg/m2 [26]. Besides,
intra-patient dose titration is routinely performed with
axitinib in order to increase axitinib exposure in patients
who do not develop hypertension. Indeed, it has been
shown that higher drug exposure and diastolic blood pres-
sure were independently associated with longer PFS and
OS, and with a higher probability of partial response in
mRCC patients [27]. This tends to demonstrate that
diastolic blood pressure could be a potential marker of
efficacy. Finally, a well-described and reproducible assess-
ment of metabolic toxicity might be a useful biomarker to
predict efficacy in the drug development process [28].
Our study suggested that biological toxicities of mTORi
(hypophosphatemia, hyperglycemia, and increase in liver
transaminases) were significantly correlated with mTORi
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efficacy and lymphopenia with lack of efficacy. Given this
preliminary result, it seems difficult to use a single bio-
logical parameter or a single descriptive method to predict
treatment efficacy on the basis of toxicity. The relationship
between a greater number of toxicities and clinical benefit
should be investigated but we did not assess these rela-
tionships because of the sample size in our series.
Conclusion
Our retrospective study suggested that hypophosphate-
mia, hyperglycemia, and increase in liver transaminases
were significantly correlated with mTORi efficacy and
lymphopenia with lack of efficacy. On the other hand,
hypercholesterolemia and hypertriglyceridemia had no
relationship with antitumoral efficacy of mTORi.
We noticed that the time to severe toxicity was short
with a median time of 28 to 56 days, highlighting that
toxicities occurred earlier than the first tumor assess-
ment (84 days). These interesting results require to be
prospectively confirmed on a larger and independent
cohort of patients.
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